MedTrace Logo

Residual Exacerbations With Mepolizumab

NCT04578171 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-02-10

No results posted yet for this study

Summary

This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.

Conditions

Interventions

DRUG

Mepolizumab

100 mg subcutaneous injections every four weeks

Sponsors & Collaborators

Principal Investigators

  • Andréanne Côté, MD · IUCPQ-UL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2027-01-31
Completion
2028-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04578171 on ClinicalTrials.gov